Company intelligence / Profile preview

PGP Glass

Ownership: Private
Employees: ~3664
Development stage: Other

Overview

PGP Glass supplies high-quality pharmaceutical-grade glass containers including Type I borosilicate and Type II/III flint and amber vials and bottles for injectable drugs, oncology products, lyophilized products, syrups, tablets, droppers and more[1][8][10]. The company operates globally with state-of-the-art manufacturing facilities certified to international standards such as ISO 15378[8]. It does not conduct clinical trials or have a therapeutic pipeline. The company was formerly known as Piramal Glass before its acquisition by Blackstone in March 2021[6]. It serves the global pharma industry with compliant packaging solutions.

Industry: Chemicals & Materials

Partnerships

Not specified in search results; likely partners with major global pharma companies as customers.

Beyond the preview

Go deeper on PGP Glass.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PGP Glass.

Explore the full profile